Share

March 15, 2016; 86 (11) Article

Metabotropic glutamate receptor type 1 autoimmunity

Clinical features and treatment outcomes

A. Sebastian Lopez-Chiriboga, Lars Komorowski, Tania Kümpfel, Christian Probst, Shannon R. Hinson, Sean J. Pittock, Andrew McKeon
First published February 17, 2016, DOI: https://doi.org/10.1212/WNL.0000000000002476
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
500

Share

Article Information

vol. 86 no. 11 1009-1013
DOI: 
https://doi.org/10.1212/WNL.0000000000002476
PubMed: 
26888994
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received August 27, 2015
  • Accepted in final form November 30, 2015
  • First Published February 17, 2016.

Article Versions

Copyright & Usage: 
© 2016 American Academy of Neurology

Author Disclosures

    1. A. Sebastian Lopez-Chiriboga, MD,
    2. Lars Komorowski, PhD,
    3. Tania Kümpfel, MD,
    4. Christian Probst, PhD,
    5. Shannon R. Hinson, PhD,
    6. Sean J. Pittock, MD and
    7. Andrew McKeon, MD
  1. A. Sebastian Lopez-Chiriboga, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Lars Komorowski, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Employee of EUROIMMUN AG.

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Tania Kümpfel, MD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. I have received travel expenses and personal compensations for lectures from Teva, Merck-Serono,Genzyme,Novartis Pharma and Biogen Idec

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Christian Probst, PhD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Euroimmun, full-time employee

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. Euroimmun

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Shannon R. Hinson, PhD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Sean J. Pittock, MD and
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. Dr. Pittock and Mayo Clinic have a financial interest in patents (#12/678,350 filed 2010 and #12/573,942 filed 2008) that relate to functional AQP4/NMO-IgG assays and NMO-IgG as a cancer marker;

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Dr. Pittock has provided consultation to Alexion Pharmaceuticals, Medimmune and Chugai Pharma USA but has received no personal fees or personal compensation for these consulting activities. All compensation for consulting activities is paid directly to Mayo Clinic.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Dr. Pittock has received a research grant from Alexion pharmaceuticals for his investigator-initiated study entitled

    Research Support, Government Entities:

    1. RO1 NS065829-01

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Guthy Jackson Charitable Foundation grant for NMO research

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Andrew McKeon, MD
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Medimmune, Inc

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (A.S.L.-C.), Mayo Clinic, Jacksonville, FL; Institute of Experimental Immunology (L.K., C.P.), Euroimmun AG, Lubeck; Department of Neuroimmunology (T.K.), Ludwig Maximilian University, Munich, Germany; and Departments of Laboratory Medicine and Pathology (S.R.H., S.J.P., A.M.) and Neurology (S.J.P., A.M.), Mayo Clinic, Rochester, MN.
  1. Correspondence to Dr. McKeon: mckeon.andrew{at}mayo.edu
View Full Text

Article usage

Article usage: February 2016 to April 2022

AbstractFullPdfSource
Feb 2016510049Highwire
Mar 201615864589Highwire
Apr 2016332920Highwire
May 2016187710Highwire
Jun 2016143712Highwire
Jul 201611583Highwire
Aug 20167477Highwire
Sep 20166887Highwire
Oct 20167444Highwire
Nov 20164774Highwire
Dec 20166562Highwire
Jan 20175411Highwire
Feb 20175234Highwire
Mar 20173612Highwire
Mar 2017085pmc
Apr 20175322Highwire
Apr 201791216pmc
May 20175323Highwire
May 2017141514pmc
Jun 20174144Highwire
Jun 2017465pmc
Jul 20171810Highwire
Jul 2017255pmc
Aug 20172500Highwire
Aug 2017121113pmc
Sep 20172042Highwire
Sep 20176108pmc
Oct 20174114Highwire
Oct 201781615pmc
Nov 20172132Highwire
Nov 201771717pmc
Dec 20172112Highwire
Jan 20184042Highwire
Feb 20182600Highwire
Mar 20182310Highwire
Apr 20182094Highwire
Apr 2018103136pmc
May 20183933Highwire
Jun 20182744Highwire
Jun 201881817pmc
Jul 20181611Highwire
Aug 20181611Highwire
Aug 20182910pmc
Sep 20182211Highwire
Oct 20181555Highwire
Nov 20182953Highwire
Dec 20183431Highwire
Jan 20191331Highwire
Feb 20192442Highwire
Mar 20192332Highwire
Apr 20193024Highwire
May 20192801Highwire
Jun 20192210Highwire
Jul 20192736Highwire
Aug 20192022Highwire
Sep 20192624Highwire
Oct 20192603Highwire
Nov 20193611Highwire
Dec 20193022Highwire
Jan 20202021Highwire
Feb 20203006Highwire
Mar 20203675Highwire
Apr 20201725Highwire
May 20203035Highwire
Jun 20201825Highwire
Jul 20202755Highwire
Aug 20202401Highwire
Sep 20201711Highwire
Oct 202032102Highwire
Nov 20202720Highwire
Dec 20202931Highwire
Jan 20213400Highwire
Feb 20212411Highwire
Mar 20212892Highwire
Apr 20211611Highwire
May 20213015Highwire
Jun 20213811Highwire
Jul 20212710Highwire
Aug 20212630Highwire
Sep 20211000Highwire
Oct 20212421Highwire
Nov 20211802Highwire
Dec 20212610Highwire
Jan 20223020Highwire
Feb 20223111Highwire
Mar 20221611Highwire
Apr 20222661Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Topics Discussed

Alert Me